RxDoctor Payments Data

Ryan Conrad, MD

Neurology · Mooresville, NCNPI 1346289402

Payments from drug & device makers

$25,707in general payments, 2019–2025

Across 1,415 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Inspire Medical Systems, Inc.$2K
  • Novartis$1K
  • Sanofi$1K
  • Biogen$1K
  • UCB, Inc.$1K
  • plus $16K from 54 others

What the payments were for

  • Speaking & faculty fees$3291%
  • Travel & lodging$8603%
  • Food & beverage$24,46895%
  • Education$510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)237$2,590
Inspire Medical Systems, Inc.15$1,623
Novartis93$1,390
Sanofi66$1,169
Biogen56$1,110
UCB, Inc.53$1,072
Lilly USA, LLC57$1,054
TG Therapeutics, Inc.34$1,020
Teva Pharmaceuticals USA, Inc.54$988
Lundbeck LLC60$924
Neurelis, Inc.52$838
Bristol Myers Squibb61$832
SK Life Science, Inc.46$787
MDD US Operations, LLC31$765
Pfizer38$716
AstraZeneca25$544
Avanir Pharmaceuticals, Inc.32$524
EMD Serono, Inc.17$501
Supernus Pharmaceuticals, Inc.29$436
Acadia Pharmaceuticals Inc25$415
Biohaven Pharmaceuticals, Inc.25$402
Jazz Pharmaceuticals Inc.18$370
Eisai Inc.12$346
Neurocrine Biosciences, Inc.18$320
Sumitomo Pharma America, Inc.15$307
Genentech USA, Inc.13$290
Sunovion Pharmaceuticals Inc.16$282
Amgen16$272
Biohaven Pharmaceutical Holding Company Ltd.26$257
Merz Pharmaceuticals, LLC10$226
Otsuka America Pharmaceutical, Inc.6$191
Takeda Pharmaceuticals U.S.A., Inc.9$190
Acorda Therapeutics, Inc8$182
Argenx US, Inc.6$175
Mallinckrodt Enterprises LLC10$164
Arbor Pharmaceuticals, Inc.7$145
Tanabe Pharma America, Inc.7$134
Aucta Pharmaceuticals, Inc.8$126
Axsome Therapeutics, Inc.4$117
Mallinckrodt Hospital Products Inc.5$115
Sandoz4$107
Avadel CNS Pharmaceuticals, LLC5$106
Upsher-smith Laboratories LLC5$89
ANI Pharmaceuticals, Inc.4$88
Amneal Pharmaceuticals LLC4$78
GRT US Holding, Inc.5$72
Impel Pharmaceuticals LLC3$70
Johnson & Johnson(2 entities)4$70
Idorsia Pharmaceuticals US Inc3$63
Harmony Biosciences LLC3$59
Octapharma USA, Inc.3$58
Kedrion Biopharma, Inc.3$51
Greenwich Biosciences, Inc.3$49
Scilex Pharmaceuticals Inc.2$48
Assertio Therapeutics, Inc.3$47
Bausch Health US, LLC3$47
E.r. Squibb & Sons, L.L.C.3$46
Vertical Pharmaceuticals, LLC3$44
Adamas Pharmaceuticals, Inc.2$42
Aquestive Therapeutics, Inc.2$40

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,707 in reported general payments places this provider in the 75th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,290,349
Medicare patients
410
Services billed
46,448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4626$359,774
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5012$318,922
Kesimpta PenOfatumumab17$171,719
RebifInterferon Beta-1a/Albumin13$158,670
MayzentSiponimod11$107,124
NuplazidPimavanserin Tartrate21$103,714
CopaxoneGlatiramer Acetate16$95,941
Nurtec OdtRimegepant Sulfate55$66,013
Aimovig AutoinjectorErenumab-Aooe51$64,686
BotoxOnabotulinumtoxina40$56,785
XcopriCenobamate30$42,050
NuedextaDextromethorphan Hbr/Quinidine23$41,422
QuliptaAtogepant34$38,373
NeuproRotigotine15$25,059
GeodonZiprasidone Hcl13$24,226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Rebif$501$158,67013 claims
AbbVieBotox, Qulipta, Ubrelvy, Namzaric$2,590$131,769113 claims
NovartisMayzent$1,390$107,12411 claims
Acadia Pharmaceuticals IncNuplazid$415$103,71421 claims
PfizerNurtec Odt, Geodon, Eliquis$716$97,02180 claims
Teva Pharmaceuticals USA, Inc.Copaxone$988$95,94116 claims
UCB, Inc.Neupro, Briviact, Vimpat$1,072$61,01540 claims
SK Life Science, Inc.Xcopri$787$42,05030 claims
Avanir Pharmaceuticals, Inc.Nuedexta$524$41,42223 claims
Eisai Inc.Fycompa$346$16,91713 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$190$7,74713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 566 neurology providers in North Carolina.

Other neurology in Mooresville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →